Skip to main content

Remote Job Finders (RJF)

AbbVie Plunks Down $2.1B for Capstan and Its Novel CAR T Therapies

The all-cash buyout, which gives AbbVie access to Capstan Therapeutics’ in vivo edited CAR T therapy for B cell–mediated autoimmune diseases, adds to a growing sense of momentum in M&A, according to BMO Capital Markets.

Novartis Makes Potential $750M+ Bet Per Cardiovascular Disease Target in Another Flagship Pact

Flagship Pioneering’s ProFound Therapeutics will use its proprietary technology to mine the expanded proteome for novel cardiovascular therapeutics. Novartis has promised to pay up to $750 million per target, though it has not specified how many targets it will go after.
Scroll to top